JP2024528731A - 眼癌転移を予防するためのイブジラスト - Google Patents

眼癌転移を予防するためのイブジラスト Download PDF

Info

Publication number
JP2024528731A
JP2024528731A JP2024505211A JP2024505211A JP2024528731A JP 2024528731 A JP2024528731 A JP 2024528731A JP 2024505211 A JP2024505211 A JP 2024505211A JP 2024505211 A JP2024505211 A JP 2024505211A JP 2024528731 A JP2024528731 A JP 2024528731A
Authority
JP
Japan
Prior art keywords
day
ibudilast
cancer
acceptable salt
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528731A5 (https=
Inventor
和子 松田
アンブロジーニ，グラツィア
ケー． シュヴァルツ，ゲーリー
ジェイ． ライ，アレックス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of JP2024528731A publication Critical patent/JP2024528731A/ja
Publication of JP2024528731A5 publication Critical patent/JP2024528731A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024505211A 2021-07-26 2022-07-25 眼癌転移を予防するためのイブジラスト Pending JP2024528731A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225820P 2021-07-26 2021-07-26
US63/225,820 2021-07-26
PCT/US2022/038157 WO2023009425A1 (en) 2021-07-26 2022-07-25 Ibudilast for preventing eye cancer metastasis

Publications (2)

Publication Number Publication Date
JP2024528731A true JP2024528731A (ja) 2024-07-30
JP2024528731A5 JP2024528731A5 (https=) 2025-07-31

Family

ID=82851760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505211A Pending JP2024528731A (ja) 2021-07-26 2022-07-25 眼癌転移を予防するためのイブジラスト

Country Status (6)

Country Link
US (1) US12005049B2 (https=)
EP (1) EP4376838A1 (https=)
JP (1) JP2024528731A (https=)
CN (1) CN117940128A (https=)
CA (1) CA3226898A1 (https=)
WO (1) WO2023009425A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395747B1 (en) 1998-08-10 2002-05-28 Sauro Sakoda Remedies for multiple sclerosis
JP4954085B2 (ja) 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
US8138201B2 (en) 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
EP2858635A1 (en) * 2012-06-11 2015-04-15 The Regents of The University of California Inhibitors of hippo-yap signaling pathway
KR102462638B1 (ko) 2014-11-26 2022-11-03 메디시노바, 인크. 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법
WO2018119262A1 (en) 2016-12-22 2018-06-28 Medicinova, Inc. Methods of treating glioblastoma multiforme using ibudilast
ES2959799T3 (es) 2018-02-12 2024-02-28 Medicinova Inc Métodos para suprimir células supresoras de origen mieloide en pacientes
JP2021512921A (ja) 2018-02-12 2021-05-20 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
WO2020076809A1 (en) 2018-10-09 2020-04-16 Medicinova, Inc. Combination of ibudilast and interferon-beta and methods of using same
CN112804999B (zh) 2018-10-19 2024-03-15 美迪诺亚公司 通过异丁司特治疗眼科疾病/病症或损伤的方法
EP4034090A1 (en) 2019-09-23 2022-08-03 MediciNova, Inc. Ibudilast oral formulations and methods of using same
CA3174413A1 (en) 2020-04-06 2021-10-14 Yuichi Iwaki Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
WO2022164948A1 (en) 2021-01-29 2022-08-04 Medicinova, Inc. Methods of treating chemical gas exposure
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
CA3231869A1 (en) 2021-09-21 2023-03-30 Medicinova, Inc. Ibudilast in combination therapy for use in the treatment of glioblastoma
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
CN118973574A (zh) 2022-02-01 2024-11-15 美迪诺亚公司 异丁司特治疗新冠肺炎后遗症的用途

Also Published As

Publication number Publication date
US12005049B2 (en) 2024-06-11
CN117940128A (zh) 2024-04-26
CA3226898A1 (en) 2023-02-02
US20230037014A1 (en) 2023-02-02
EP4376838A1 (en) 2024-06-05
WO2023009425A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
EP2913047B1 (en) Pulmonary disease-specific therapeutic agent
JP2025020319A (ja) テルリプレシン組成物およびその使用方法
JP2024528731A (ja) 眼癌転移を予防するためのイブジラスト
JP2020504721A (ja) イブジラストを使用した多形膠芽腫の治療方法
ES2959799T3 (es) Métodos para suprimir células supresoras de origen mieloide en pacientes
JP7652763B2 (ja) イブジラスト経口製剤およびその使用方法
US12171752B2 (en) Methods of treating post-COVID condition(s)
US20220409627A1 (en) Treatment of lower airways disorders
US20230090534A1 (en) Methods of treating glioblastoma multiforme using combination therapy
US20220241252A1 (en) Methods of treating chemical gas exposure
US12042485B2 (en) Methods of minimizing cancer metastasis
JP2022504435A (ja) イブジラストとインターフェロン－ベータとの組み合わせ、およびそれを使用する方法
JP2024517694A (ja) インターロイキン－１受容体アンタゴニストの組成物
HK40014065B (en) Terlipressin composition for use in treating ascites

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250723

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250823